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Abstract   
 
 
Background: Recently, massive increases in health care costs for the diagnosis and 
management of skin lesions have been observed (2000-2005).  The aim of this study 
was to describe the health system costs attributed to the diagnosis and management of 
suspicious skin lesions detected during a trial of a population melanoma screening 
program (1998-2001)  Setting: Queensland, Australia.  Methods: Data from the trial 
and Medicare Australia were used to categorise and cost all suspicious skin lesions 
arising from the trial included general practitioner consultations, 
diagnosis/management and pathology.  Comparisons were made with other screened 
and unscreened populations. Results: Overall, 2,982 lesions were treated within the 
trial producing a mean cost of A$118 per lesion. Excisions for benign lesions 
contributed the greatest proportion of total costs (45%).  The total cost burden was 
approximately 10% higher for males than females, and 63% of overall costs were for 
persons aged ≥ 50 years. For diagnosis and management procedures, the estimated 
average cost per 1000 individuals was $A23,560 for men ≥ 50 years from the skin 
cancer screening trial, compared to $A26,967 for BreastScreen Australia and $A3,042 
for the National Cervical Screening Program.  Conclusions:  The proportion of costs 
for benign skin lesions and biopsies arising from the screening program were no 
higher than in the two-year period outside the trial.  Diagnostic and management costs 
for skin cancer as a result of screening is comparable to those for breast and cervical 
cancer, if screening is targeted at men ≥ 50 years.  
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Introduction 
Skin cancer continues to be a major public health issue in countries with fair-skinned 
populations.  In Australia in 2001, 8,885 new cases of melanoma were diagnosed 
among a population of approximately 19 million.(1) Those residing in the state of 
Queensland carry the world’s highest risk for melanoma with an estimated life time 
risk of 1 in 17 for men and 1 in 25 for women.(2) Between 1993-2003, the incidence 
of melanoma in the United Kingdom grew rapidly by 42% and 27% for men and 
women, respectively leading to 8,000 new cases diagnosed in 2002.(3)  In addition, 
over 374,000 people in Australia (4) and over 65,000 people in the United Kingdom 
were treated for nonmelanoma skin cancer (NMSC) in 2002.(3)  Primarily due to this 
very high incidence (rather than the high cost per treatment) NMSCs were the most 
expensive cancer to the Australian health system in 2000-01 and represent a 
substantial economic burden.(4)  Treatment expenditure from 1993-94 to 2000-01 
increased in real terms by 24% and 56% for NMSCs and melanoma, respectively.(4)   
 
At present skin cancers are diagnosed outside a formal screening program. In both the 
UK and Australia, GPs remain at the front line in the diagnosis and management of 
suspicious skin lesions.  With respect to skin cancer, Medicare claims data over the 
last 10 years have shown substantial increases in the numbers of services for 
diagnosis, management and pathology of skin lesions (5) and their associated costs.  
Unlike the pigmented lesion clinics in the UK which require referral from a GP, in 
Australia, and especially Queensland, there has been a rapid expansion during the last 
five years of open-access GP-operated skin clinics.  The contribution of these clinics, 
to informal skin screening activity in Queensland has risen significantly between 1999 
and 2003.  Recommendations from leading national health authorities in the UK and 
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Australia do not support mass population screening for melanoma or other skin 
cancers (6), as conclusive evidence from randomised trials on the effectiveness of 
population screening in reducing mortality from melanoma is unavailable. However, 
there is indication from a large case-control study that melanomas detected during a 
deliberate skin examination (by a doctor or a lay-person) are thinner compared to 
those detected incidentally.(7)   
 
Three exploratory economic analyses have modelled estimates of the cost per life year 
saved from melanoma screening and concluded screening could be an efficient use of 
health resources if targeted at men over 50 years (8-10).  These studies relied heavily 
on hypothetical cohorts and simulation modelling around assumed parameter values.  
This is due to the link between screening and decreased detection of thicker lesions 
(and subsequent reductions in mortality) remains to be established.  This link is an 
essential prerequisite for the ‘effectiveness’ side of a strong cost-effectiveness 
analysis.  For this reason, we have chosen to examine the immediate cost impact to 
the health system based on confirmed diagnostic and treatment pathways in our cohort 
and not an extensive cost-effectiveness analysis. 
 
A large-scale cluster randomised controlled trial of population screening for 
melanoma began in 1998, in Queensland, Australia.  The key aim of the trial was to 
determine the effectiveness of a community-based screening program in reducing 
mortality from melanoma.  During the trial, 18 rural and regional communities were 
recruited with nine communities randomised each in the control and intervention arms 
(aggregate population 63,000 adults ≥ 30 years).  In the absence of sufficient numbers 
of thick melanomas during the trial, we could not conduct a full economic evaluation 
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of this screening program (e.g., cost-effectiveness, cost-benefit analysis).  However, 
we were in the position to establish the costs to the Australian public health care 
system of skin cancer management within, compared to outside, this designated 
screening program.  This paper specifically aims to: 1) describe the costs to the health 
system for diagnosis, management and pathology of suspicious skin lesions detected 
during a screening trial; and 2) compare the proportion of costs generated for 
suspicious skin lesion management through the screening trial compared to all 
persons residing in the trial communities.  We expected higher absolute and 
proportional costs for treatment of benign skin lesions as part of a concentrated 
screening effort.    
Methods 
The intervention, called SkinWatch, was designed to promote whole-body skin self-
examination and whole-body skin examination by a general practitioner (GP) 
(referred to here as clinical skin examination) (11).  The SkinWatch intervention 
comprised a community education and awareness program, an education program for 
local GPs to improve their diagnostic and treatment skills and the provision of free, 
open-access skin screening clinics.(12)  Clinics were conducted in workplaces and 
local community venues. Clinics were promoted in local newspapers, and in addition, 
random samples of men and women in each community were sent letters inviting 
them to attend the clinics. The clinics were staffed by both medical practitioners from 
within the community in addition to hiring medical practitioners from outside. Unlike 
pigmented lesion clinics in the UK where referral is required by a GP, doctors 
working within SkinWatch clinics did not treat any suspicious skin lesions (and no 
consultation costs were assigned to this screening examination in the subsequent 
analysis) but rather referred the patient back to their GP for diagnosis and 
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management.  The research team retained copies of all referrals. Patients who did not 
fill their referrals within two months were reminded by telephone or mailing and 
another reminder was issued five months after the referral was recived. Upon visit by 
their own GP, the GPs used the SkinWatch clinic referral forms for record keeping 
(age and sex of patient, location, clinical diagnosis and subsequent management of 
suspicious skin lesions) and attached histopathology reports for any excised or 
biopsied lesions and patient surveys (demographic information, history of skin 
screening behaviours and skin cancer risk factors).  Sociodemographic profiles of the 
attendees of the SkinWatch clinics were similar to those of the communities however 
twice as many clinic attendees were aged 50-69 years.  Further details of the project 
design, methods, tools and scope have been described previously.(11, 12)    
 
Costing Analysis 
We took a health provider perspective and used patient-level clinical data to focus on 
the diagnosis and management costs of skin lesions. We assessed whether the 
randomised trial of population melanoma screening was associated with increased 
benign skin lesion activity, and subsequent costs.  Data on the management, 
histopathologic diagnosis, and site of each lesion referred from the SkinWatch clinics 
within the intervention communities were collated for the costing analysis.  Medicare 
is Australia’s national health insurance scheme provided by the Commonwealth 
Government to all Australian residents of any age.  It provides free or subsidised 
treatment by GPs for many medical services including attendances, procedures and 
pathology services. The Medicare Benefit Schedule (MBS) was used to categorise and 
assign a cost to each lesion in this analysis.(13)  The size of the lesion was also 
required before a cost could be assigned however these data were not collected in the 
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trial.  Therefore, this information was imputed by using national MBS Item 
Reports.(5)  MBS items for management of lesions according to size were 
summarised for 1995-1999 (1,348,000 claims) and proportions of each size category 
generated (i.e., ≤10 mm, 11-20 mm, >20 mm).  The same proportions were then 
randomly assigned to the sample of referred lesions in this project.  For lesions that 
were treated by cryotherapy, the clinical diagnosis was used because no pathology 
diagnosis was recorded.  Together these lesion data enabled a MBS item number and 
corresponding cost to be assigned to each referred lesion.  A total of 33 items were 
possible for skin lesion treatment and included lesion type (melanoma, SCC or BCC, 
benign lesion, etc.), management path (cryotherapy, excision, biopsy, etc.), lesion size 
and site.  As a result of the initial referral, MBS items were also assigned for a 
standard GP consultation (for all persons who went to their GP after a SkinWatch 
referral), any resulting pathology services for skin lesion work-up and referrals to 
specialists.  Data on the use of further primary cancer treatment services (e.g., 
radiation, chemotherapy etc), patient out-of-pocket expenses or private practitioner 
expenses were not collected within the trial and not included in this analysis. 
 
Costs are reported in 2004 Australian dollars and are based on Medicare unit costs.  
The current comparative price level based on OECD purchasing power parities is £1 = 
$AU 0.92.(14)  As it was possible to have more than one lesion per patient, the 
means, medians and total costs were generated and summarised per lesion and per 
patient where appropriate.  Results were produced for costs by broad cost type (i.e., 
GP consultation, diagnosis/management, and histopathology), broad lesion 
management type (i.e., melanoma excisions, SCC/BCC excisions, benign lesion 
excisions, biopsies, ‘other treatments’ and referral to specialist), gender and age.   
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‘Other treatments’ included cryotherapy, topical creams, shave excisions, laser 
phototherapy, curettage and ablation techniques.   
 
For comparison, additional Medicare data were obtained on the same MBS items for 
the entire population within the intervention and control communities of the trial, 
identified by postcode, during 2001 to 2002, the closest time period to the trial for 
which data were available from Medicare.  Medicare data captures all services 
performed by registered providers, from services eligible for MBS claims and for 
which a claim has been processed.  As a source of medical care utilisation, this data is 
recommended above patient-supplied data in Australia(15).  The analysis was 
undertaken using the computer program ‘SPSS Version 13.0 for Windows’.(16) 
 
Results 
From 1998 to 2001, 16,383 skin examinations were conducted within the SkinWatch 
clinics in the intervention communities.  A total of 2,302 patients (14.1%) and 4,129 
lesions were referred from the SkinWatch clinics back to their own GP.  For 480 
patients, no record of attendance at the doctor was received.  Medical practitioner 
attendance records were therefore available for 1,822 patients presenting with 2,982 
suspicious skin lesions.  Further details on the clinical and secondary outcomes of this 
project are available elsewhere.(17) 
 
A summary of health system costs of the SkinWatch clinics for the GP attendance, 
diagnosis, management and pathology required of the suspicious skin lesions, by 
broad cost type, is provided in Table 1.  The mean cost per patient was A$193 and 
mean cost per lesion A$118.  The mean cost per lesion is lower than the median cost 
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(A$128) due to many patients requiring only a GP consultation with no further 
action/management required.  The total health system cost for the diagnosis and 
treatment of the 2,982 skin lesions referred during this trial was A$352,533.   The 
largest component of total costs were diagnosis and management costs A$168,146 or 
48%, followed by pathology services A$136,557 or 38% (Table 1). 
 
Insert Table 1 here 
 
Table 2 summarises costs by broad management group (i.e., by grouped MBS item 
codes as shown) and includes the standard cost of a GP consultation and any 
subsequent pathology services.  As expected, the management strategy that incurred 
the greatest total cost (and number of lesions) was for benign lesion excisions 
A$159,684 or 45% of total costs.  This was followed by SCC/BCC excisions at 
A$77,257 or 22% and other treatments (e.g., cryotherapy, topical creams, etc.) 
A$61,613 or 18%.  Mean cost per lesion was highest for malignant melanomas due to 
the more complex excision(s) and pathology resources needed.  Mean costs per lesion 
were relatively high for SCC/BCC excisions, lesions with multiple strategies and 
benign lesion excisions. 
 
Insert Table 2 here 
 
Total costs were examined by gender and age group in Table 3.  More males than 
females were referred for suspicious skin lesions (1,615 vs 1,367), and subsequently, 
overall costs for males were approximately A$30,000 or 10% higher.  Sixty-three 
percent of total costs were incurred by men and women aged ≥ 50 years.  Mean cost 
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per patient was similar for males and females, A$119 versus A$117, respectively.  
Males were treated for more lesions across all age groups compared to females and 
consequently higher absolute costs.   
 
Insert Table 3 here 
 
We compared the costs generated in the trial through SkinWatch referrals with all 
Medicare claims data generated for the intervention and control communities 
separately (2001-2002), excluding the costs of GP consultations and referrals to 
specialists (Table 4).  A similar percentage of total cost for excised melanomas 
occurred in the SkinWatch clinics (2.0%) compared to that recorded for all claims for 
the intervention (1.9%) and control communities (1.4%) during 2001-2002.  The 
proportion of costs for excisions of SCC or BCCs were lower for the SkinWatch 
group (15.8%) compared to all claims for the intervention (19.3%) and control 
communities (18.8%) and were similar for benign lesion excisions (26.0%) compared 
to (28.0%) and (27.9%), for intervention and control communities, respectively.  This 
was unexpected because we believed higher quantities of benign lesions would result 
from a screening program. 
 
Insert Table 4 here 
 
Discussion 
The mean and median costs of diagnosis and management per lesion arising from a 
population screening program for melanoma  were A$118 and A$127, respectively 
(A$193 mean per patient).  Mean costs per lesion were greatest for melanoma and 
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SCC/BCC excisions, due to their more extensive and complex treatment and 
pathology needs.  Excisions of benign skin lesions made up the greatest component of 
total costs (45.3%) followed by SCC/BCC excisions (21.9%).  The total cost burden 
was approximately 10% higher for males than females, and 63% of overall costs were 
for persons aged ≥ 50 years.  Our data appear consistent with three previous economic 
analyses predicting greater efficiencies if screening was targeted for men over 50 
since there is potential for greater cost-savings and benefits to occur in this cohort. (8-
10) 
 
Compared to all skin cancers managed for the intervention and control communities 
in a 2-year period outside the trial (2001-2002), referrals from the SkinWatch clinics 
resulted in a higher cost percentage of melanoma excisions, ‘other treatments’ and 
linked pathology services.  Also, we found that the proportion of costs for excisions 
for SCC/BCC, benign lesions and biopsies were slightly lower for referrals from the 
SkinWatch clinics.  Although these proportional differences are small, a shift which 
reduces or contains the huge absolute numbers (and associated total costs) for NMSCs 
is desirable in terms of health care expenditure.  
 
The rate of abnormalities (defined as number of screenees with a suspected lesion 
requiring further tests or treatment, over all screenees) from SkinWatch was 14.1% 
compared to 8.9% from BreastScreen Australia (2002)(18) and 1.8% from the 
National Cervical Screening Program (2002)(19).  For each of the three screening 
programs, we obtained average diagnosis/management costs from MBS unit costs per 
suspected cancer as well as confirmed abnormality rates and generated ratios of ‘cost 
per 1000 individuals screened’.  These costs do not include all costs attributable to the 
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screening programs (advertising, infrastructure etc).  The estimated average cost per 
1000 individuals was A$27,118 for SkinWatch for persons ≥ 50 years (A$23,560 for 
men ≥ 50 only), compared to A$26,967 for BreastScreen Australia and A$3,042 for 
the National Cervical Screening Program.  While comparisons across screening 
programs are difficult, and our results do not include costs of all the activities of the 
SkinWatch program, it would appear that a population melanoma screening program 
in Australia may generate diagnostic and management costs comparable to those of 
BreastScreen Australia.  These costs would be even lower if screening was targeted at 
older men only.  Moreover, after diagnosis and excision procedures, and compared to 
other screening programs, most patients with melanoma do not require costly surgical 
and hospitalisation-related resources but instead are treated primarily in ambulant 
settings by GPs, surgeons or dermatologists.   
 
Some limitations of our study should be noted.  The community-based intervention 
was provided for regional and rural populations and it may not be possible to 
generalise findings to urban environments.  This study was focused on the time of 
primary diagnosis and management only and excluded any subsequent management 
and follow-up costs for malignant lesions.  However, estimated to be of greater 
magnitude, we have also not assessed any potential cost-savings and it is unknown 
whether early management of malignant cancers within the trial has lead to potential 
long-term savings of expensive adjuvant treatments for lesions diagnosed at a later 
stage.  In contrast, this kind of assessment has been undertaken for breast cancer 
screening (20), concluding that future costs would partially offset public health 
investment in screening.  Finally, we have not included costs attributable to the 
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establishment and operation of the screening program (essentially a research project) 
but have instead concentrated on the immediate cost implications to the health system. 
 
This paper has provided insights into costs associated with detection and management 
of suspicious skin lesions during a melanoma screening trial. There is some indication  
that screening for melanoma could have costs comparable to other screening efforts 
and does not seem to unduly increase the proportional costs associated with biopsy or 
excision of benign lesions compared to management in usual care.  In the absence of 
mass melanoma screening, identifying mechanisms to reduce the increasing toll skin 
cancer has on the health system and increasing cost-efficiencies should be a research 
and policy priority. 
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Table 1.  Summary of Medicare costs1 for diagnosis and management of suspicious skin lesions referred from SkinWatch Clinics 
 
 Patients (n=1,822) Lesions (n=2,982)   
Cost type Mean cost  Median cost  Mean cost  Median cost  Total cost % Total cost 
 $Aus $Aus $Aus $Aus $Aus  
 
Medical practitioner 
consultation2  26 
 
26  16   16    47,831 14% 
 
Diagnosis/Management3 92 
 
69  56 
  
38  168,146 48% 
 
Histopathology4   75 
 
83  46 
 
74  136,557 38% 
 
Total Costs $193 
 
$168 $118 
 
$128 $352,533 100% 
1. MBS 2004 85% benefit (maximum reimbursement from Medicare) 
2. Assumed a standard primary care physician consultation up to 20 minutes in duration = MBS item 23. 
3. MBS items included 31300-31335, 31255-31290, 31200-31210, 30071, 30192-30205, 104 
4. MBS items for pathology of skin lesions included 72816-18, 72830. 
 
 17
 
Table 2.  Summary of total costs1 by lesion management group 
 
Management group2 MBS items 
No. 
lesions 
Mean cost 
per lesion 
$Aus 
Median cost 
per lesion 
$Aus 
Total cost 
$Aus % Total cost 
Excisions:       
    -  Melanoma3 31300-31335 294   387   374     11,219 3% 
    -  SCC/BCC  31255-31290 329   235    223     77,257 22% 
    -  Benign lesions  31200-31210 893   179    168    159,684 45% 
Biopsies 30071 139   131     128    18,194 5% 
Other treatments5 30192-30205 764   81     62     61,613 18% 
Referral to specialist 104 40 78 78 3,112 1% 
No treatment/monitor n/a 756 16  16  12,126 3% 
Multiple treatments multiple 32 292  235  9,329 3% 
Total  2,982 $118 $128  $352,533 100% 
 
1. Includes cost of consultation, diagnosis, management and pathology MBS codes where relevant. 
2. Grouped by MBS codes according to similar lesion type or treatment 
3. This group of lesion excisions includes Hutchinson’s melanotic freckle. 
4. This excludes 4 melanomas that required multiple treatment and therefore included in the ‘multiple treatments’ category. 
5. ‘Other treatments’ includes cryotherapy, topical creams, shave excision, laser phototherapy, curettage, ablation technique. 
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Table 3.  Summary of costs1 by gender and age group  
 
 
No. 
lesions 
Mean cost 
per lesion 
$Aus 
Median cost 
per lesion 
$Aus 
No. 
patients 
Mean cost 
per patient 
$Aus 
Median cost 
per patient 
$Aus 
Total cost 
$Aus 
% Total 
cost 
Males         
< 30 years 112 132 159 79 187 159 14,781 8% 
30-49 years 479 114 134 292 187 159 54,579 28% 
≥ 50 years 1,024 120 128 587 209 179 122,817 64% 
Subtotal 1,615 119  958 201 174 192,177 55% 
Females         
< 30 years 98 111 159 74 147 159 10,889 7% 
30-49 years 429 116 134 284 176 159 49,914 31% 
≥ 50 years 840 119 125 506 197 173 99,553 62% 
Subtotal 1,367 117  864 186 159 160,356 45% 
Total 2,982   1,822   $352,533 100% 
1. Includes cost of consultation, diagnosis, management and pathology MBS codes where relevant. 
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Table 4.  Proportional distribution of total costs1 of SkinWatch  
referrals (1998-2001) and all Medicare claims2 recorded in the intervention and control communities (2001-2002) 
 
 
 SkinWatch Referrals Intervention Communities3 Control Communities 
 (1998-2001) (2001-2002) (2001-2002) 
Management group 
(MBS codes) % % % 
Melanoma excisions  
(31300-31335) 
2.0 1.9 1.4 
SCC/BCC excisions  
(31255-31290) 15.8 19.3 18.8 
Excisions of benign lesions 
(31200-31210) 26.0 28.0 27.9 
Biopsies  
30071 1.8 3.4 3.2 
Other treatments4  
(30192-30205) 8.5 5.5 6.7 
Pathology of skin lesions  
(72816-18, 72830) 46.0 41.9 42.0 
Total 100 100 100 
Total costs1 Aus$ $297,058  $1,529,345  $1,123,698 
 
1. Costs exclude GP consultation fees and referrals to specialists. 
2. Medicare Australia takes care in the compilation and provision of the information and data, it does not assume or accept any liability for the accuracy, quality, 
suitability and currency of the information or data. 
3. This represents population-based claims data on the communities in the trial. 
4. ‘Other treatments’ includes cryotherapy, topical creams, shave excision, laser phototherapy, curettage, ablation technique. 
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Acronym list 
 
 
BCC  Basal cell carcinoma 
SCC  Squamous cell carcinoma 
NMSC  Non-melanoma skin cancer 
MBS  Medicare Benefit Schedule 
US  United States 
 
 
